AstraZeneca Says Wainua Trial Failed to Meet Primary Goal
By Andrea Figueras
AstraZeneca said the trial for its Wainua drug on a rare type of heart disease didn't meet its primary objective, at a time when the company's drug pipeline outside oncology is in focus.
The U.K. drugmaker said Thursday that Wainua was generally well tolerated, with a safety profile consistent with previous results. However, it failed to meet the primary efficacy endpoint compared with placebo when treating transthyretin amyloid cardiomyopathy.
Transthyretin amyloid cardiomyopathy is an underdiagnosed and potentially fatal disease of the heart muscle in which a protein called transthyretin builds up in the heart, nerves and other organs.
The trial examined the role of Wainua, a gene silencer treatment, on top of today's standard of care in reducing recurring cardiovascular events and mortality. Adding Wainua didn't provide a statistically significant benefit, it said.
The company's data for pipeline drugs outside its core oncology business, including Wainua, has been under the radar and was expected to boost the business. Analysts at Jefferies had expected AstraZeneca's potential entry into the market for a heart disease could open up revenue potential of $5 billion or more.
AstraZeneca and Ionis are jointly developing and commercializing Wainua in the U.S., while the former has exclusive rest of world commercialization and development rights.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
July 09, 2026 02:47 ET (06:47 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
3 of the Best Core Stocks to Own
3 Great New ETFs From 2026
The 10 Best Companies to Invest in Now
United States